

## **ISOGENICA COLLABORATES WITH BIOFOUNDRY BIOTECH PHENOTYPECA THROUGH SMART GRANT AWARD**

March 17th 2022

Isogenica are collaborating with Phenotypeca, a biofoundry business who create and own yeast synthetic biology solutions to make any recombinant protein, including biologic drugs.

The collaboration has been fuelled through a SMART grant from Innovate UK worth a total value of £405,794. The project aims to develop a unique yeast breeding platform for optimised protein manufacture by enhancing protein folding performance, reduce proteolysis for secreted proteins and to create a best-in-class system for Isogenica's high-value products as VHH antibody-based therapeutics, including multi-specific molecules.

Phenotypeca's focus and drive combined with their innate scientific curiosity is the perfect blend for pushing innovation. By bringing our antibody expertise to the collaboration, we hope to facilitate the development of scaled-up production methods we can use to generate high-quality products at lower cost-of-goods.

Isogenica's collaboration with Phenotypeca will enhance protein folding performance and reduce bioprocess issues for secreted proteins to create a best-in-class system for these high-value pharmaceutical products. Phenotypeca's platform will deploy yeast expression for VHHs to accelerate drug candidate selection, while identifying novel multivalent VHH constructs for cancer therapy products and providing yeast strains for commercial manufacture.

### **About Isogenica**

Isogenica specialises in single-domain biotherapeutics (VHH antibodies).

In collaboration with biopharmaceutical partners Isogenica has developed a deep pipeline including two clinical assets and numerous partnered discovery and pre-clinical stage programs.

Isogenica's library is fully synthetic, providing a key advantage that VHH are generated to specific epitopes which are difficult to target using conventional immunisation methods. Isogenica's library can be displayed in phage or in the company's proprietary CIS Display technology. Using our proprietary platform and technology, we deliver therapeutic antibodies that meet the highest standards of quality and developability. Isogenica's team specialise in discovery projects from target QC to Candidate selection.

VHH represent an ideal format for incorporation in CAR-T, T-cell engaging therapeutics, Antibody Radio Conjugates, Antibody Drug Conjugates and bispecific and multispecific formats. These



#### **Isogenica Limited**

The Mansion, Chesterford Research Park  
Little Chesterford, Essex, CB10 1XL, UK  
Tel: +44(0)1799 533680

Registered in England No. 3571781  
VAT No. GB 125 4384 23



antibodies are developed to a target product profile with carefully designed affinities, valencies and specificities enabling refined tumour cell targeting and modes of action.

**For more information:**

Visit: [www.isogenica.com](http://www.isogenica.com)

Contact: Mandeep Sehmi, Associate Director Marketing

T: +44 1799 533 680 E: [mandeep.sehmi@isogenica.com](mailto:mandeep.sehmi@isogenica.com)



**Isogenica Limited**

The Mansion, Chesterford Research Park  
Little Chesterford, Essex, CB10 1XL, UK  
Tel: +44(0)1799 533680

Registered in England No. 3571781  
VAT No. GB 125 4384 23